awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q55056081-039DA030-C9F1-4520-A398-DF08F8267CFC
Q55056081-039DA030-C9F1-4520-A398-DF08F8267CFC
BestRank
Statement
http://www.wikidata.org/entity/statement/Q55056081-039DA030-C9F1-4520-A398-DF08F8267CFC
Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose.
P2860
Q55056081-039DA030-C9F1-4520-A398-DF08F8267CFC
BestRank
Statement
http://www.wikidata.org/entity/statement/Q55056081-039DA030-C9F1-4520-A398-DF08F8267CFC
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
b447f6a938b995aeff542ba78a38caa1e27e77b1
P2860
Phase I study of MLN8237--investigational Aurora A kinase inhibitor--in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia.